Ever wondered which stocks an artificial intelligence (AI)-powered analyst would pick? Here at TipRanks, we have created a robust A.I. Stock Analyst called Spark that eliminates the biases and errors that could possibly be created by a human analyst. TipRanks’ AI Stock Analyst is trained on an extensive financial data reservoir and evaluates stocks based on fundamental, technical, and sentiment-based indicators, all presented in an easy-to-digest format. It also describes both positive and negative factors, company financials, and short- and long-term momentum signals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
We leveraged the A.I. Analyst Top Stocks Screener to identify the three healthcare stocks that TipRanks A.I. Analyst is bullish on. Moreover, we filtered for stocks with Wall Street’s “Strong Buy” consensus rating, indicating high optimism from analysts about their long-term potential.
Here Are the 3 Healthcare Stocks for This Week:
Krystal Biotech (KRYS) – Krystal Biotech is a biotechnology company that develops and commercializes gene therapies for the treatment of severe, life‑threatening or rare diseases. According to KRYS A.I. Stock Analysis, Krystal has a solid score of 76 and an Outperform rating. Additionally, Spark has assigned a price target of $164 for KRYS, implying 16.1% upside potential from current levels. Meanwhile, analysts have set an average KRYS price target of $200, suggesting 42% upside.
Krystal’s overall stock rating is supported by strong financial performance and strategic global expansion efforts, coupled with robust cash flow and low leverage. Anticipated short-term revenue declines and operational challenges present notable risks, but these are balanced by the company’s strategic initiatives and market expansion.
DexCom (DXCM) – DexCom is a medical device company that specializes in developing and marketing of continuous glucose monitoring (CGM) systems in the U.S. and internationally. According to DXCM A.I. Stock Analysis, DexCom has a solid score of 73 and an Outperform rating. Additionally, Spark has assigned a price target of $87 for DXCM, implying nearly 11% upside potential from current levels. Meanwhile, analysts have set an average Dexcom price target of $100.28, suggesting a nearly 28% upside.
DXCM’s strong financial performance and positive earnings call insights have contributed to the high stock score. Despite the stock’s high valuation, technical weaknesses, and current market sentiment, DexCom’s strategic initiatives and innovation support a positive outlook.
Corcept Therapeutics (CORT) – Corcept Therapeutics is a biopharmaceutical company focused on developing medicines to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. According to CORT A.I. Stock Analysis, Corcept has a solid score of 73 and an Outperform rating. Additionally, Spark has assigned a price target of $79, implying 10.1% upside potential from current levels. Meanwhile, analysts have set an average CORT price target of $134.50, suggesting a massive 87% upside.
Corcept’s overall stock rating is supported by strong financial performance and positive earnings call sentiment, and strategic growth initiatives. However, mixed technical indicators, high P/E (price-to-earnings) ratio, and operational challenges present moderate risks.
Visit the TipRanks A.I. Analyst Screener to analyze stocks across different sectors and market capitalizations.